CAPR The Lancet Publishes HOPE-3 Data for Capricor Therapeutics' Deramiocel in Duchenne Muscular Dystrophy -SM
CAPR The Lancet Publishes HOPE-3 Data for Capricor Therapeutics' Deramiocel in Duchenne Muscular Dystrophy -SM
Story updates
02:09:33 PM UTC
SquawkNews
CAPR Capricor says Phase 3 HOPE-3 trial shows deramiocel slows upper limb decline 54% in Duchenne muscular dystrophy
02:11:18 PM UTC
SquawkNews
CAPR The Lancet Publishes HOPE-3 Data for Capricor Therapeutics' Deramiocel in Duchenne Muscular Dystrophy -SM
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.